All In Biotech

Drug Trial Radar · NCT06351527

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Patients With Mature B-cell Malignancies

Last checked: Nov 19, 2026Latest source record: Jun 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

78

Planned (sponsor's estimate)

Start

Apr 23, 2024

Primary completion

Jun 25, 2027

Study completion Oct 25, 2027

Sponsor

Lead sponsor
InnoCare Pharma Inc.Industry
Sponsor type
Industry
First posted
Apr 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ICP-248 as monotherapy or in combination with anti-CD20 monoclonal antibody in Mature B-cell Malignancies

Conditions

  • Mature B-cell Malignancies

Interventions

  • ICP-248Drug

    ICP-248 will be administered orally once daily at escalated doses (starting dose 5/10 mg, maximum 150 mg).

  • Obinutuzumab (G)Drug

    Obinutuzumab will be administered by IV infusion at a dose of 100 mg or 1000 mg, depending on splitting rules, at Cycle 1, Day 1 (if 100 mg was received on Day 1, 900 mg will be administered on Cycle 1, Day 2); 1000 mg at Cycle 1, Day 8 and Day 15; 1000 mg at Day 1 for all subsequent cycles until the end of Cycle 6.

  • Rituximab (R)Drug

    Rituximab will be administered by IV infusion at a dose of 375 milligrams per square meter (mg/m\^2) at Day 1 per week for 4 weeks during cycle 1, then on day 1 of cycles 3-8, and thereafter once every other cycle up to 2 years.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLTTime frame: 49 days
  2. Safety and tolerability of ICP-248 at different doses in B-cell malignanciesTime frame: 5 years

Locations

8 sites in 3 countries. Site status is shown where the registry gives one.

  • BRCR Medical Center

    Plantation, Florida · Recruiting

  • Clinical Research Alliance

    Westbury, New York · Recruiting

  • Pan American Center for Oncology Trials

    San Juan, Puerto Rico · Recruiting

  • CNE CCOHTPC of Cherkasy Regional Council

    Cherkasy, Ukraine · Recruiting

  • CNE"City Clin Hosp#4"of Dnipro City Council

    Dnipro, Ukraine · Recruiting

  • Medical Center of Limited Liability Company Arensia Exploratory Medicine

    Kyiv, Ukraine · Recruiting

  • Med Center 'Ok!Clinic+' of International Institute of Clinical Trials LLC

    Kyiv, Ukraine · Recruiting

  • SI Institute of Blood Pathology and Transfusion Medicine of AMSU

    Lviv, Ukraine · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.